Medtech knees constant-currency sales growth measures knee product revenue growth after removing foreign-currency translation effects.
Stryker reported 8.0% constant-currency growth in Knees for the second quarter of 2026. Revenue was $693M, up from $640M.
International growth exceeded U.S. growth
U.S. Knees revenue grew 6.2%, while international revenue increased 12.4% on a constant-currency basis.
The geographic split helps distinguish broad category growth from regional mix.
Revenue growth does not equal procedure growth
Knee sales can change with procedure volume, implant mix, pricing, robotics adoption, and geography.
Pair it with Hips constant-currency sales growth and Orthopaedics operating margin.
Primary source: Stryker Q2 2026 Form 10-Q.
Part of the Medtech Product Family Economics
See It in Company Research
These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.
- SYKOpen operating-model research →10 of 10 reviewed concepts in Medtech Product Family EconomicsOrthopaedics product growth4 of 4 bridge concepts supportedContinue through this bridge:Hips Constant-Currency GrowthOrtho Tech Constant-Currency GrowthTrauma & Extremities Constant-Currency Growth
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare knee product growth
Compare knee revenue growth while keeping implant mix, procedure demand, robotics adoption, pricing, and geography separate.
Explore more topics in the Financial Research Encyclopedia.